2157 Stock Overview
A biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for cancer targeted therapy and immunotherapy in China and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Lepu Biopharma Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$3.47 |
| 52 Week High | HK$6.50 |
| 52 Week Low | HK$2.63 |
| Beta | -0.37 |
| 11 Month Change | -17.58% |
| 3 Month Change | -9.40% |
| 1 Year Change | -38.37% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -51.40% |
Recent News & Updates
Shareholder Returns
| 2157 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -3.3% | 0.5% | -2.4% |
| 1Y | -38.4% | -34.5% | 0.6% |
Return vs Industry: 2157 underperformed the Hong Kong Biotechs industry which returned -34.5% over the past year.
Return vs Market: 2157 underperformed the Hong Kong Market which returned 0.6% over the past year.
Price Volatility
| 2157 volatility | |
|---|---|
| 2157 Average Weekly Movement | 13.0% |
| Biotechs Industry Average Movement | 8.6% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in HK Market | 14.8% |
| 10% least volatile stocks in HK Market | 3.7% |
Stable Share Price: 2157's share price has been volatile over the past 3 months.
Volatility Over Time: 2157's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 429 | Ziye Sui | www.lepubiopharma.com |
Lepu Biopharma Co., Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for cancer targeted therapy and immunotherapy in China and internationally. The company offers PUYOUHENG (Pucotenlimab Injection), a humanized IgG4 mAb against human PD-1 for the treatment of solid tumors and melanoma. It is also developing MRG003 that is in phase III clinical study for treating nasopharyngeal cancer, and head and neck squamous cell carcinoma; and MRG002, which is in phase III trials to treat breast and urothelial cancer, as well as HER2-positive.
Lepu Biopharma Co., Ltd. Fundamentals Summary
| 2157 fundamental statistics | |
|---|---|
| Market cap | HK$5.61b |
| Earnings (TTM) | -HK$23.75m |
| Revenue (TTM) | HK$242.19m |
24.5x
P/S Ratio-250.0x
P/E RatioIs 2157 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2157 income statement (TTM) | |
|---|---|
| Revenue | CN¥225.35m |
| Cost of Revenue | CN¥28.28m |
| Gross Profit | CN¥197.08m |
| Other Expenses | CN¥219.17m |
| Earnings | -CN¥22.10m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.013 |
| Gross Margin | 87.45% |
| Net Profit Margin | -9.81% |
| Debt/Equity Ratio | 78.1% |
How did 2157 perform over the long term?
See historical performance and comparison